Symbols / DRUG Stock $88.67 -0.49% Bright Minds Biosciences Inc.
DRUG (Stock) Chart
Stock Fundamentals
|
|
|
|
|
|
About
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company's BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York.
Ratings
Current target
$87.87
Low
$146.02
High
$194.67
Mean
$162.76
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-04-13 | init | Jefferies | — → Buy | $145 |
| 2026-03-30 | reit | BTIG | Buy → Buy | $147 |
| 2026-03-04 | main | HC Wainwright & Co. | Buy → Buy | $145 |
| 2026-02-17 | main | BTIG | Buy → Buy | $147 |
| 2026-01-07 | main | BTIG | Buy → Buy | $147 |
| 2026-01-06 | main | BTIG | Buy → Buy | $147 |
| 2026-01-02 | main | Chardan Capital | Buy → Buy | $80 |
| 2025-12-30 | reit | HC Wainwright & Co. | Buy → Buy | $115 |
| 2025-09-15 | reit | HC Wainwright & Co. | Buy → Buy | $85 |
| 2025-09-08 | init | BTIG | — → Buy | $72 |
| 2025-08-19 | reit | HC Wainwright & Co. | Buy → Buy | $85 |
| 2025-05-21 | main | Chardan Capital | Buy → Buy | $80 |
| 2025-05-13 | init | TD Cowen | — → Buy | — |
| 2025-05-07 | init | Chardan Capital | — → Buy | $80 |
| 2025-02-19 | reit | HC Wainwright & Co. | Buy → Buy | $85 |
| 2025-01-23 | init | Piper Sandler | — → Overweight | $93 |
| 2025-01-10 | init | Cantor Fitzgerald | — → Overweight | — |
| 2025-01-10 | init | HC Wainwright & Co. | — → Buy | $85 |
| 2024-11-25 | init | Baird | — → Outperform | $75 |
- Eli Lilly stock soars after Q1 earnings as revenue grows 56% on strength of GLP-1 drug sales - Yahoo Finance hu, 30 Apr 2026 16
- Bristol Myers Reports Surprise Sales Growth, But There's A Caveat - Investor's Business Daily hu, 30 Apr 2026 16
- Erasca Stock Sinks 48% in Race for Pancreatic Cancer Miracle Drug. What’s Behind the Sell-Off. - Barron's ue, 28 Apr 2026 20
- 10 Best Health Care Stocks to Buy for 2026 - U.S. News Money ue, 28 Apr 2026 20
- A New GLP-1 Challenger? Early Data Shows Viking's New Obesity Drug Tops Novo Rival - Stocktwits hu, 30 Apr 2026 08
- This drug stock nears a buy point, with profit set to explode - MSN Wed, 29 Apr 2026 15
- Erasca stock sinks almost 50% after patient death in cancer drug trial - qz.com Wed, 29 Apr 2026 14
- Stock Market Today, April 28: Erasca Plunges After Patient Death in Early Cancer Drug Trial - The Motley Fool ue, 28 Apr 2026 21
- -5.04% for Hims & Hers stock as weight-loss drug guidelines take center stage - Traders Union Wed, 29 Apr 2026 08
- Cancer Drug Developer Erasca Sinks by Record 55% After Patient Death - Bloomberg.com ue, 28 Apr 2026 21
- We're exiting our position in a drug stock and initiating a stake in a more attractive rival - CNBC Wed, 08 Apr 2026 07
- Lilly is selling $12.9 billion of GLP-1 drugs every three months — and expects to sell even more - MarketWatch hu, 30 Apr 2026 10
- This Drug Stock Nears A Buy Point, With Profit Set To Explode - Investor's Business Daily Mon, 27 Apr 2026 17
- Lilly’s Next Obesity Drug Could Be the Real Catalyst for the Stock - Barron's Mon, 27 Apr 2026 19
- AXSM Stock In Spotlight Ahead Of Key FDA Verdict On Alzheimer’s Drug This Week - Stocktwits Wed, 29 Apr 2026 09
Financials
Statement View
| Line Item | Trend | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
13.94
+393.76%
|
2.82
-61.78%
|
7.39
-50.68%
|
14.98
|
| Research And Development |
|
11.08
+839.36%
|
1.18
-76.40%
|
5.00
-58.95%
|
12.18
|
| Selling General And Administration |
|
2.57
+77.47%
|
1.45
-34.29%
|
2.20
-13.77%
|
2.55
|
| Selling And Marketing Expense |
|
0.43
+932.83%
|
0.04
-65.16%
|
0.12
-78.36%
|
0.55
|
| General And Administrative Expense |
|
2.14
+52.12%
|
1.40
-32.51%
|
2.08
+4.06%
|
2.00
|
| Salaries And Wages |
|
0.50
+0.71%
|
0.49
-57.30%
|
1.16
+1063.06%
|
0.10
|
| Other Gand A |
|
1.64
+80.02%
|
0.91
-1.48%
|
0.92
-51.37%
|
1.90
|
| Other Operating Expenses |
|
0.29
+45.88%
|
0.20
+5.64%
|
0.19
-23.21%
|
0.24
|
| Total Expenses |
|
13.94
+393.76%
|
2.82
-61.78%
|
7.39
-50.68%
|
14.98
|
| Operating Income |
|
-13.94
-393.76%
|
-2.82
+61.78%
|
-7.39
+50.68%
|
-14.98
|
| EBITDA |
|
-13.86
-404.13%
|
-2.75
+62.41%
|
-7.31
+51.14%
|
-14.97
|
| Normalized EBITDA |
|
-14.05
-412.74%
|
-2.74
+62.61%
|
-7.33
+51.08%
|
-14.98
|
| Reconciled Depreciation |
|
0.08
+4.79%
|
0.07
+1.25%
|
0.07
+1100.10%
|
0.01
|
| EBIT |
|
-13.94
-393.76%
|
-2.82
+61.78%
|
-7.39
+50.68%
|
-14.98
|
| Total Unusual Items |
|
0.19
+2127.15%
|
-0.01
-165.63%
|
0.01
+39.78%
|
0.01
|
| Total Unusual Items Excluding Goodwill |
|
0.19
+2127.15%
|
-0.01
-165.63%
|
0.01
+39.78%
|
0.01
|
| Special Income Charges |
|
—
|
0.00
|
0.00
+100.00%
|
-0.00
|
| Impairment Of Capital Assets |
|
—
|
0.00
|
0.00
-100.00%
|
0.00
|
| Net Income |
|
-12.23
-336.46%
|
-2.80
+61.99%
|
-7.37
+50.74%
|
-14.96
|
| Pretax Income |
|
-12.23
-336.46%
|
-2.80
+61.99%
|
-7.37
+50.74%
|
-14.96
|
| Net Non Operating Interest Income Expense |
|
1.52
+4942.54%
|
0.03
|
0.00
|
0.00
|
| Net Interest Income |
|
1.52
+4942.54%
|
0.03
|
0.00
|
0.00
|
| Interest Income Non Operating |
|
1.52
+4942.54%
|
0.03
|
0.00
|
0.00
|
| Interest Income |
|
1.52
+4942.54%
|
0.03
|
0.00
|
0.00
|
| Other Income Expense |
|
0.19
+2127.15%
|
-0.01
-165.63%
|
0.01
+39.78%
|
0.01
|
| Other Non Operating Income Expenses |
|
—
|
—
|
—
|
-0.24
|
| Gain On Sale Of Security |
|
0.19
+2127.15%
|
-0.01
-165.63%
|
0.01
+16.77%
|
0.01
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-12.23
-336.46%
|
-2.80
+61.99%
|
-7.37
+50.74%
|
-14.96
|
| Net Income From Continuing Operation Net Minority Interest |
|
-12.23
-336.46%
|
-2.80
+61.99%
|
-7.37
+50.74%
|
-14.96
|
| Net Income From Continuing And Discontinued Operation |
|
-12.23
-336.46%
|
-2.80
+61.99%
|
-7.37
+50.74%
|
-14.96
|
| Net Income Continuous Operations |
|
-12.23
-336.46%
|
-2.80
+61.99%
|
-7.37
+50.74%
|
-14.96
|
| Normalized Income |
|
-12.42
-344.67%
|
-2.79
+62.19%
|
-7.39
+50.68%
|
-14.98
|
| Net Income Common Stockholders |
|
-12.23
-336.46%
|
-2.80
+61.99%
|
-7.37
+50.74%
|
-14.96
|
| Diluted EPS |
|
-1.78
-173.85%
|
-0.65
+67.17%
|
-1.98
+67.33%
|
-6.06
|
| Basic EPS |
|
-1.78
-173.85%
|
-0.65
+67.17%
|
-1.98
+67.33%
|
-6.06
|
| Basic Average Shares |
|
6.88
+59.58%
|
4.31
+15.87%
|
3.72
+50.57%
|
2.47
|
| Diluted Average Shares |
|
6.88
+59.58%
|
4.31
+15.87%
|
3.72
+50.57%
|
2.47
|
| Diluted NI Availto Com Stockholders |
|
-12.23
-336.46%
|
-2.80
+61.99%
|
-7.37
+50.74%
|
-14.96
|
| Total Other Finance Cost |
|
—
|
—
|
—
|
—
|
| Line Item | Trend | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|---|
| Total Assets |
|
84.42
+1282.92%
|
6.10
-11.26%
|
6.88
-43.09%
|
12.09
|
| Current Assets |
|
84.31
+1308.22%
|
5.99
-12.12%
|
6.81
-42.98%
|
11.95
|
| Cash Cash Equivalents And Short Term Investments |
|
82.91
+1349.43%
|
5.72
-15.23%
|
6.75
-41.97%
|
11.63
|
| Cash And Cash Equivalents |
|
82.91
+1349.43%
|
5.72
-15.23%
|
6.75
-41.97%
|
11.63
|
| Cash Equivalents |
|
0.09
+0.00%
|
0.09
+0.00%
|
0.09
+0.00%
|
0.09
|
| Cash Financial |
|
82.82
+1370.09%
|
5.63
-15.43%
|
6.66
-42.28%
|
11.54
|
| Receivables |
|
0.41
+722.46%
|
0.05
+35.81%
|
0.04
-76.26%
|
0.16
|
| Other Receivables |
|
—
|
—
|
—
|
0.04
|
| Taxes Receivable |
|
0.21
+317.96%
|
0.05
+35.81%
|
0.04
-67.71%
|
0.11
|
| Accrued Interest Receivable |
|
0.20
|
0.00
|
—
|
—
|
| Prepaid Assets |
|
0.99
+356.04%
|
0.22
+682.28%
|
0.03
-83.16%
|
0.16
|
| Total Non Current Assets |
|
0.11
-4.84%
|
0.12
+77.16%
|
0.07
-52.17%
|
0.14
|
| Net PPE |
|
0.11
-4.84%
|
0.12
+77.16%
|
0.07
-52.17%
|
0.14
|
| Gross PPE |
|
0.11
-4.84%
|
0.12
+77.16%
|
0.07
-52.17%
|
0.14
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Other Properties |
|
—
|
—
|
—
|
0.14
|
| Leases |
|
0.11
-4.84%
|
0.12
+77.16%
|
0.07
-52.17%
|
0.14
|
| Goodwill And Other Intangible Assets |
|
—
|
—
|
—
|
0.00
|
| Total Liabilities Net Minority Interest |
|
2.38
+318.23%
|
0.57
+102.33%
|
0.28
-81.82%
|
1.54
|
| Current Liabilities |
|
2.34
+341.73%
|
0.53
+88.24%
|
0.28
-80.93%
|
1.47
|
| Payables And Accrued Expenses |
|
2.25
+400.97%
|
0.45
+116.73%
|
0.21
-85.24%
|
1.40
|
| Payables |
|
1.71
+319.65%
|
0.41
+123.55%
|
0.18
-85.37%
|
1.25
|
| Accounts Payable |
|
1.71
+319.65%
|
0.41
+123.55%
|
0.18
-85.37%
|
1.25
|
| Current Accrued Expenses |
|
0.54
+1194.70%
|
0.04
+67.00%
|
0.03
-84.19%
|
0.16
|
| Current Debt And Capital Lease Obligation |
|
0.08
+6.48%
|
0.08
+7.93%
|
0.07
+8.27%
|
0.07
|
| Current Capital Lease Obligation |
|
0.08
+6.48%
|
0.08
+7.93%
|
0.07
+8.27%
|
0.07
|
| Total Non Current Liabilities Net Minority Interest |
|
0.04
+4.23%
|
0.04
|
0.00
-100.00%
|
0.07
|
| Long Term Debt And Capital Lease Obligation |
|
0.04
+4.23%
|
0.04
|
0.00
-100.00%
|
0.07
|
| Long Term Capital Lease Obligation |
|
0.04
+4.23%
|
0.04
|
0.00
-100.00%
|
0.07
|
| Stockholders Equity |
|
82.04
+1381.93%
|
5.54
-16.09%
|
6.60
-37.41%
|
10.54
|
| Common Stock Equity |
|
82.04
+1381.93%
|
5.54
-16.09%
|
6.60
-37.41%
|
10.54
|
| Capital Stock |
|
123.25
+247.93%
|
35.42
+4.45%
|
33.91
+5.20%
|
32.24
|
| Common Stock |
|
123.25
+247.93%
|
35.42
+4.45%
|
33.91
+5.20%
|
32.24
|
| Share Issued |
|
7.64
+68.78%
|
4.52
+19.94%
|
3.77
+7.21%
|
3.52
|
| Ordinary Shares Number |
|
7.64
+68.78%
|
4.52
+19.94%
|
3.77
+7.21%
|
3.52
|
| Retained Earnings |
|
-46.58
-35.60%
|
-34.35
-8.88%
|
-31.55
-30.50%
|
-24.17
|
| Gains Losses Not Affecting Retained Earnings |
|
5.37
+34.12%
|
4.01
+17.87%
|
3.40
+37.09%
|
2.48
|
| Total Equity Gross Minority Interest |
|
82.04
+1381.93%
|
5.54
-16.09%
|
6.60
-37.41%
|
10.54
|
| Total Capitalization |
|
82.04
+1381.93%
|
5.54
-16.09%
|
6.60
-37.41%
|
10.54
|
| Working Capital |
|
81.97
+1401.84%
|
5.46
-16.44%
|
6.53
-37.65%
|
10.48
|
| Invested Capital |
|
82.04
+1381.93%
|
5.54
-16.09%
|
6.60
-37.41%
|
10.54
|
| Total Debt |
|
0.13
+5.73%
|
0.12
+61.74%
|
0.07
-47.43%
|
0.14
|
| Capital Lease Obligations |
|
0.13
+5.73%
|
0.12
+61.74%
|
0.07
-47.43%
|
0.14
|
| Net Tangible Assets |
|
82.04
+1381.93%
|
5.54
-16.09%
|
6.60
-37.41%
|
10.54
|
| Tangible Book Value |
|
82.04
+1381.93%
|
5.54
-16.09%
|
6.60
-37.41%
|
10.54
|
| Other Equity Interest |
|
—
|
0.46
-45.23%
|
0.83
|
—
|
| Line Item | Trend | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-8.69
-369.77%
|
-1.85
+73.66%
|
-7.02
+48.30%
|
-13.59
|
| Cash Flow From Continuing Operating Activities |
|
-8.69
-369.77%
|
-1.85
+73.66%
|
-7.02
+48.30%
|
-13.59
|
| Net Income From Continuing Operations |
|
-12.23
-336.46%
|
-2.80
+61.99%
|
-7.37
+50.74%
|
-14.96
|
| Depreciation Amortization Depletion |
|
0.08
+4.79%
|
0.07
+1.25%
|
0.07
+1100.10%
|
0.01
|
| Depreciation |
|
0.08
+4.79%
|
0.07
+1.25%
|
0.07
+1100.10%
|
0.01
|
| Depreciation And Amortization |
|
0.08
+4.79%
|
0.07
+1.25%
|
0.07
+1100.10%
|
0.01
|
| Other Non Cash Items |
|
0.04
+300.79%
|
0.01
-54.71%
|
0.02
-32.88%
|
0.03
|
| Stock Based Compensation |
|
3.18
+279.00%
|
0.84
-27.11%
|
1.15
+31.66%
|
0.88
|
| Asset Impairment Charge |
|
—
|
0.00
|
0.00
-100.00%
|
0.00
|
| Operating Gains Losses |
|
-0.31
-2987.96%
|
-0.01
-122.33%
|
0.05
+117.52%
|
-0.26
|
| Net Foreign Currency Exchange Gain Loss |
|
-0.31
-2987.96%
|
-0.01
-122.33%
|
0.05
+117.52%
|
-0.26
|
| Change In Working Capital |
|
0.55
+1294.00%
|
0.04
+104.23%
|
-0.94
-230.05%
|
0.72
|
| Change In Receivables |
|
-0.36
-2639.92%
|
-0.01
-111.15%
|
0.12
+360.33%
|
-0.05
|
| Change In Prepaid Assets |
|
-0.77
-308.22%
|
-0.19
-238.17%
|
0.14
+3519.30%
|
0.00
|
| Change In Payables And Accrued Expense |
|
1.69
+598.01%
|
0.24
+120.21%
|
-1.20
-256.30%
|
0.77
|
| Change In Other Current Liabilities |
|
—
|
—
|
—
|
0.00
|
| Financing Cash Flow |
|
85.57
+10456.43%
|
0.81
-62.98%
|
2.19
-57.86%
|
5.20
|
| Cash Flow From Continuing Financing Activities |
|
85.57
+10456.43%
|
0.81
-62.98%
|
2.19
-57.86%
|
5.20
|
| Net Issuance Payments Of Debt |
|
-0.10
-11.61%
|
-0.09
-4.20%
|
-0.09
-1102.35%
|
-0.01
|
| Repayment Of Debt |
|
-0.10
-11.61%
|
-0.09
-4.20%
|
-0.09
-1102.35%
|
-0.01
|
| Long Term Debt Payments |
|
-0.10
-11.61%
|
-0.09
-4.20%
|
-0.09
-1102.35%
|
-0.01
|
| Net Long Term Debt Issuance |
|
-0.10
-11.61%
|
-0.09
-4.20%
|
-0.09
-1102.35%
|
-0.01
|
| Net Common Stock Issuance |
|
82.10
+9021.95%
|
0.90
-26.08%
|
1.22
-69.83%
|
4.03
|
| Proceeds From Stock Option Exercised |
|
3.93
+1301295.70%
|
0.00
-99.97%
|
1.09
-44.87%
|
1.97
|
| Net Other Financing Charges |
|
-0.36
|
—
|
-0.03
+96.63%
|
-0.80
|
| Changes In Cash |
|
76.88
+7494.66%
|
-1.04
+78.50%
|
-4.83
+42.38%
|
-8.39
|
| Effect Of Exchange Rate Changes |
|
0.31
+2567.45%
|
0.01
+125.84%
|
-0.05
-117.52%
|
0.26
|
| Beginning Cash Position |
|
5.72
-15.23%
|
6.75
-41.97%
|
11.63
-41.15%
|
19.76
|
| End Cash Position |
|
82.91
+1349.43%
|
5.72
-15.23%
|
6.75
-41.97%
|
11.63
|
| Free Cash Flow |
|
-8.69
-369.77%
|
-1.85
+73.66%
|
-7.02
+48.30%
|
-13.59
|
| Common Stock Issuance |
|
82.10
+9021.95%
|
0.90
-26.08%
|
1.22
-69.83%
|
4.03
|
| Issuance Of Capital Stock |
|
82.10
+9021.95%
|
0.90
-26.08%
|
1.22
-69.83%
|
4.03
|
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|